BXT Stock Overview
Engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BioNxt Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.53 |
| 52 Week Low | CA$0.10 |
| Beta | 0.55 |
| 11 Month Change | -29.86% |
| 3 Month Change | -33.90% |
| 1 Year Change | -40.91% |
| 33 Year Change | -83.59% |
| 5 Year Change | n/a |
| Change since IPO | -90.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -14.1% | -4.8% | 0.8% |
| 1Y | -40.9% | -19.4% | 2.0% |
Return vs Industry: BXT underperformed the German Pharmaceuticals industry which returned -19.4% over the past year.
Return vs Market: BXT underperformed the German Market which returned 2% over the past year.
Price Volatility
| BXT volatility | |
|---|---|
| BXT Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BXT's share price has been volatile over the past 3 months.
Volatility Over Time: BXT's weekly volatility has decreased from 20% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Hugh A. Rogers | www.bionxt.com |
BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.
BioNxt Solutions Inc. Fundamentals Summary
| BXT fundamental statistics | |
|---|---|
| Market cap | €21.59m |
| Earnings (TTM) | -€5.32m |
| Revenue (TTM) | €141.05k |
153.1x
P/S Ratio-4.1x
P/E RatioIs BXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXT income statement (TTM) | |
|---|---|
| Revenue | CA$206.74k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$206.74k |
| Other Expenses | CA$8.01m |
| Earnings | -CA$7.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,773.05% |
| Debt/Equity Ratio | -83.5% |
How did BXT perform over the long term?
See historical performance and comparison